Drug Trial Radar · NCT05432466
Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 7, 2022
Primary completion
Mar 1, 2029
Study completion Apr 1, 2029
Sponsor
- Lead sponsor
- Acer Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.
Conditions
- Vascular Ehlers-Danlos Syndrome
Interventions
ACER-002 (celiprolol) 200 mg BIDDrug
ACER-002 (celiprolol) 200 mg BID
Placebo BIDDrug
placebo for ACER-002
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of a vEDS-related clinical event requiring medical attention: Fatal/nonfatal cardiac or arterial events [including dissection or rupture], uterine rupture, intestinal rupture, and/or unexplained sudden deathTime frame: Over the double-blind period (estimated to be 40 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Science 37
Culver City, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.